Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients

Abstract

Early clinical trials showed that treatment with anti‐programmed death‐1 (anti‐PD‐1) agents, such as nivolumab and pembrolizumab, led to marked improvements in the prognosis of advanced melanoma patients. However, most of the large‐scale studies of such treatment mainly analyzed the efficacy of anti‐PD‐1 agents in Caucasian populations. Since the clinical subtypes of melanoma differ widely among populations, and the response to anti‐PD‐1 agents is known to vary among the clinical subtypes of the disease, the efficacy of anti‐PD‐1 agents in Asian populations remains unclear.

This article is protected by copyright. All rights reserved.

https://ift.tt/2Q6aQqe